Barclays PLC Buys 9,547 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

Barclays PLC lifted its stake in UroGen Pharma Ltd. (NASDAQ:URGN) by 16.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 69,325 shares of the company’s stock after acquiring an additional 9,547 shares during the period. Barclays PLC owned 0.30% of UroGen Pharma worth $738,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in URGN. KLP Kapitalforvaltning AS bought a new position in UroGen Pharma in the fourth quarter worth about $59,000. Oppenheimer & Co. Inc. purchased a new position in shares of UroGen Pharma in the 4th quarter worth approximately $126,000. Legal & General Group Plc raised its stake in shares of UroGen Pharma by 24.6% during the 4th quarter. Legal & General Group Plc now owns 19,845 shares of the company’s stock worth $211,000 after acquiring an additional 3,920 shares in the last quarter. SG Americas Securities LLC lifted its position in UroGen Pharma by 44.1% during the fourth quarter. SG Americas Securities LLC now owns 20,269 shares of the company’s stock valued at $216,000 after acquiring an additional 6,207 shares during the last quarter. Finally, Privium Fund Management B.V. acquired a new stake in UroGen Pharma in the fourth quarter valued at approximately $295,000. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

UroGen Pharma Price Performance

NASDAQ:URGN opened at $9.69 on Wednesday. The firm’s fifty day moving average is $10.58 and its two-hundred day moving average is $11.02. The firm has a market cap of $446.78 million, a price-to-earnings ratio of -3.08 and a beta of 0.66. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. UroGen Pharma Ltd. has a one year low of $8.94 and a one year high of $20.70.

UroGen Pharma (NASDAQ:URGN) last issued its earnings results on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The firm had revenue of $24.57 million during the quarter, compared to analysts’ expectations of $25.25 million. Research analysts expect that UroGen Pharma Ltd. will post -3.12 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Guggenheim reaffirmed a “buy” rating on shares of UroGen Pharma in a research report on Tuesday, April 29th. The Goldman Sachs Group lowered their price target on UroGen Pharma from $22.00 to $16.00 and set a “neutral” rating for the company in a report on Thursday, April 17th. Scotiabank began coverage on shares of UroGen Pharma in a research report on Wednesday, April 16th. They issued a “sector outperform” rating and a $23.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $55.00 price target on shares of UroGen Pharma in a research note on Monday, April 28th. Finally, LADENBURG THALM/SH SH started coverage on shares of UroGen Pharma in a report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price target for the company. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, UroGen Pharma currently has a consensus rating of “Buy” and an average price target of $32.86.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.